Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer

NCT06521866 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

208

Enrollment

OTHER

Sponsor class

Conditions

Advanced Colorectal Carcinoma
Immunotherapy

Interventions

DRUG: Serplulimab
DRUG: Chemotherapy
RADIATION: SABR
DRUG: Targeted therapy

Sponsor

Fudan University